Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
- Status
- COMPLETED
- Phase
- PHASE2
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC
- Status
- UNKNOWN
- Phase
- PHASE1
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1